Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05065255
Other study ID # 2021-A00579-32
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 30, 2021
Est. completion date January 30, 2023

Study information

Verified date March 2022
Source Laboratoires Coloplast S.A.S
Contact Souad MEILLASSOUX, MD
Phone +33 1 56 63 17 81
Email frsme@coloplast.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To date, there is no objective data to help in the choice of the type of catheter to offer to the patient according to his or her needs. Although it is now known that the quality of life of patients practicing intermittent self catheterisation is dependent on multiple factors, there is little data on the factors that facilitate or hinder adherence to intermittent self catheterisation during the first six months after initiation of intermittent self catheterisation. The prospective multicenter exploratory observational study that the sponsor wishes to conduct aims to determine what criteria preside over patient choice of SpeedyCath (SC) leads. This information would allow us to set up a personalized advice with each patient in the future, with the aim of proposing the SC catheter best adapted to his needs. The study population will consist of adults with neurogenic or non-neurogenic urinary disorders that warrant the use of intermittent self catheterisation, with intermittent self catheterisation education occurring at the time of inclusion. Patients should be autonomous in the practice of intermittent self catheterisation, and the minimum expected duration of follow-up should be greater than or equal to 6 months. Only patients who choose to use SpeediCath leads will be included in the study.


Description:

Urinary self-catheterization consists of emptying the bladder oneself by inserting a catheter into the urethra. It is the reference method in case of dysfunctions of the bladder emptying phase, in particular in case of complete urinary retention or complete or incomplete bladder emptying with sub bladder obstruction. Neurological pathologies such as spinal cord injury, multiple sclerosis, multisystematic atrophy, peripheral neuropathies, Parkinson's disease, and stroke, may be the cause of bladder disturbances. These disturbances may also be caused by pelvic denervations as a result of enlarged pelvic surgeries or radiotherapy for the treatment of gynecological, urological or digestive cancers. The objective of the implementation of intermittent self-catheterization (ISC) is to reduce the morbidity related to bladder and bowel dysfunction and to improve the quality of life of patients by making them more autonomous. It involves a rigorous learning phase for the patient and a phase of acceptance of this new mictional mode. When ISC is indicated, training is provided to the patient to enable him/her to manage daily catheterization. The objectives of this training are to understand, perform, monitor and adapt self-care. This training, mainly provided by the nursing staff and/or a specialist physician, is usually provided during a hospitalization. After returning home, the patient continues to be monitored by the specialist physician and the nursing team to evaluate the mastery of the technique (possibly reviewing the gesture and ensuring the adequacy of the catheter), the patient's adaptation to the practice of ISC, his compliance with the associated rules (frequency and regularity of catheterization, volume of urine) and any complications. A first visit is usually made between 3 and 12 weeks, then a second one after 6 months of use. However, this therapeutic patient education (TPE), even when carried out by trained personnel, is not necessarily sufficient for immediate acceptance and adherence to self-catheterization in the medium to long term. It is important that the patient is involved in his or her choice of equipment, since the decision to self-catheterize is usually made by the physician, and that the benefits of self-catheterization outweigh the constraints. The patient must be guided and involved in the choice of catheter during this learning phase, which will ensure better compliance and future adherence to treatment. The interest of this study is therefore to better understand the real motivations of the patient in the choice of the catheter. This will undoubtedly make it possible to improve either the equipment itself or certain FTE sequences in the future by insisting on the problematic or questioning points in terms of the choice of catheter proposed to the patient by the caregiver. The determinants of the patient's choice are all the more important as there are a very large number of catheters on the market. Coloplast offers the SpeediCath® (SC) range of ready-to-use self-lubricating hydrophilic catheters. This range is designed to cover the different needs of patients, providing them with probes of different length, flexibility, shape and ergonomics. There are 3 types of catheters adapted to women (SC Standard®, SC Compact® and SC Compact Set, SC Compact Eve®), and 3 types of catheters adapted to men (SC Standard®, SC Compact® and SC Compact Set, SC Flex®). Concerning the technical specificities, a systematic review of the literature concluded that hydrophilic catheters (with a lubricant attached to the catheter) provide a benefit in terms of safety and quality of life, particularly in patients with spinal cord injuries. SC® catheters significantly reduce trauma to the urinary tract by reducing friction. Another study also showed that SpeediCath catheters were significantly faster, more convenient, and more discreet to use than a non-ready-to-use hydrophilic catheter (need to activate lubricant). The superiority of SpeediCath Compact Male and Female catheters in terms of quality of life compared to reference catheters was demonstrated in a randomized study using the specific validated ISC-Q questionnaire and has been retained and valued by the CNEDiMTS To date, there is no objective data to help in the choice of the type of catheter to propose to the patient according to his needs. Although it is now known that the quality of life of patients using ISC is dependent on multiple factors, there is little data on the factors that facilitate or hinder adherence to ISC during the first six months after initiation of ISC. The prospective multicenter exploratory observational study that the sponsor wishes to conduct aims to determine the criteria that govern patient choice of SC leads. This information would allow us to set up a personalized advice with each patient in the future, with the aim of proposing the SC catheter best adapted to his needs. The study population will consist of adults with neurogenic or non-neurogenic urinary disorders that warrant the use of ISC, with ISC education occurring at the time of inclusion. Patients should be autonomous in the practice of ISC, and the minimum expected duration of follow-up should be greater than or equal to 6 months. Only patients who have chosen to use SpeediCath leads will be included in the study. Numerous criteria will be collected to allow a detailed analysis of the modalities of choice of the type of SC probe. This collection involves the use of self-questionnaires for the patients. These questionnaires will be collected during the usual follow-up of the patient, including a visit at the time of the ASI education, a follow-up visit around 3 to 12 weeks (depending on the practices of the investigating center) and a second follow-up visit around 6 months. Acceptance of ISC will be measured by the Intermittent Catheterization Acceptance Test (I-CAT). This is a patient questionnaire developed by the Groupe d'Études de Neuro-Urologie de Langue Française (GENULF) and validated in French in 2016 during a prospective multicenter study of 201 neurological and non-neurological patients. The I-CAT allows for a better assessment and understanding of the psychological barriers encountered by patients in relation to ISC. The questionnaire consists of 14 questions, with a minimum score of 0 for perfect acceptance and a maximum score of 56 characterizing the least possible acceptance. The difficulties encountered by patients during ASI will be measured by the "Intermittent Catheterization Difficulty Questionnaire" IC-Di-Q. This is a patient questionnaire validated in French, and its purpose is to evaluate the difficulties encountered during the performance of ISA. In 13 questions, it explores numerous factors such as pain, blockage, bleeding, spasticity, and urethral sphincter spasm, in terms of frequency of occurrence and intensity. The purpose of this questionnaire is to identify the difficulties encountered by patients, and to monitor their evolution after the implementation of alternatives or solutions (including the adaptation of the type of catheter). Patient adherence to ISC will be measured by the Intermittent Catheterization Adherence Scale (I-CAS). This is a patient questionnaire validated in French with 8 questions, 7 of which have a binary answer (yes/no), and one with 5 suggested answers. The score ranges from 0 for strong adherence to ISC to 8 for very weak adherence. A study-specific self-questionnaire was also created with the support of the Scientific Advisory Board to determine the reasons for the patient's choice of catheter. This questionnaire includes criteria independent of the patient (e.g. advice from the nurse), and criteria specific to the patient (e.g. ease of use, discretion).


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date January 30, 2023
Est. primary completion date January 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female or male, 18 years of age or older - Subject having been informed of the study and having decided to participate (no opposition) - Subject affiliated to a social security system or entitled to it - Subject with neurogenic or non-neurogenic urinary disorders, justifying the use of the ISC to empty the bladder - Subjects who have received their first ISC education at the time of inclusion - Subject with an expected duration of ISC of at least 6 months - Subject has been presented with at least two types of SC catheters and has chosen to use the SpeediCath line of catheters as their first self-catheterization catheter - Able to perform ISC independently - Subjects who have been recommended by their healthcare professional to perform catheterization at least 4 times per day Exclusion Criteria: - Vulnerable subject according to the regulations in force - Pregnant, parturient or nursing woman; - Subject deprived of liberty by judicial, medical or administrative decision; - Minor subject ; - Subject protected by law or unable to give consent - Subject who is not affiliated or not a beneficiary of a social security system; - Subject falling into several of the above categories; - Subject who has refused to participate in the study - Subject participating in an interventional clinical study - Subjects who, in the opinion of the investigator, have cognitive problems that prevent them from answering a questionnaire or for whom assessment could be problematic.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SpeediCath® catheters
Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.

Locations

Country Name City State
France Centre hospitalier d'Aulnay sous bois Aulnay sous bois
France Centre Hospitalier Intercommunal Robert Ballanger Aulnay sous-bois
France Centre auterive Auterive
France Centre Calvé- Fondation Hopale Berck
France Tour de Gassies Bruges
France CHU de Caen Caen
France Centre Hospitalier William Morey Chalon-sur-Saône
France Centre médical Germaine Revel Chamalières
France Hôpitaux civil de Colmar Colmar
France CHU Le Bocage Dijon
France Hôpital Raymond Poincaré Garches
France Centre Hospitalier de Gonesse Gonesse
France CHU GrenobleAlpes La Tronche
France Hôpital Swynghedauw Lille
France CHU Limoges Limoges
France Clinique Saint Martin Marseille
France CHU de Timonnes Marsillargues
France Hôpital Lapeyronie Montpellier
France Institut Mutualiste Montpelliérain- Beau soleil Montpellier
France CHU de Nancy Nancy
France Hôpital Saint jacques Nantes
France Hôpital Pasteur 2 - CHU de Nice Nice
France Hôpital Tenon Paris
France Hôpital Universitaire Pitié-Salpêtrière Paris
France Centre PSR Perpignan
France CMMRF Kerpape Ploemeur
France CHU Reims Reims
France CHU Rennes Rennes
France Hôpital Victor Provo Roubaix
France CHU Rouen Rouen
France Hopital Charles Nicolle Rouen
France Hôpital Henry Gabrielle Saint Genis Laval
France Hôpital Bellevue, CHU de SAINT ETIENNE Saint-Étienne
France Hôpital Henry Gabrielle Saint-Genis-Laval
France Centre de l'Arche Saint-Saturnin
France Nouvel Hôpital Civil Strasbourg
France CHU Toulouse Rangueil Toulouse
France CHU Tours Tours

Sponsors (1)

Lead Sponsor Collaborator
Laboratoires Coloplast S.A.S

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient questionnaire for the choice of the catheter A study-specific self-administered questionnaire was created with the support of the Scientific Advisory Board to determine the reasons for the patient's choice of catheter. This questionnaire contains 18 questions, including criteria independent of the patient (e.g. advice from the nurse), and criteria specific to the patient (e.g. ease of use, discretion). At visit 3 : 6 months
Secondary Patient questionnaire for the choice of the catheter A study-specific self-administered questionnaire was created with the support of the Scientific Advisory Board to determine the reasons for the patient's choice of catheter. This questionnaire contains 18 questions, including criteria independent of the patient (e.g. advice from the nurse), and criteria specific to the patient (e.g. ease of use, discretion). At baseline
Secondary Patient satisfaction Determined by a 0 to 5 points visual analog scale, 0 is the worst possible satisfaction, and 5 is the best possible satisfaction At visit 2 : 3 to 12 weeks
Secondary Patient satisfaction Determined by a 0 to 5 points visual analog scale, 0 is the worst possible satisfaction, and 5 is the best possible satisfaction At visit 3 : 6 months
Secondary "Intermittent Catheterization Difficulty Questionnaire" IC-Di-Q This is a patient questionnaire validated in French.The purpose of this questionnaire is to identify the difficulties encountered by the patients and to follow their evolution after the implementation of alternatives or solutions (including the adaptation of the type of catheter). In 13 questions, it explores numerous factors such as pain, blockage, bleeding, spasticity, and urethral sphincter spasm, in terms of frequency of occurrence and intensity. At visit 2 : 3 to 12 weeks
Secondary "Intermittent Catheterization Difficulty Questionnaire" IC-Di-Q This is a patient questionnaire validated in French.The purpose of this questionnaire is to identify the difficulties encountered by the patients and to follow their evolution after the implementation of alternatives or solutions (including the adaptation of the type of catheter). In 13 questions, it explores numerous factors such as pain, blockage, bleeding, spasticity, and urethral sphincter spasm, in terms of frequency of occurrence and intensity. At visit 3 : 6 months
Secondary Catheterization Adherence Scale (I-CAS) This is a patient questionnaire validated in French with 8 questions, 7 of which have a binary response (yes/no), and one with 5 suggested answers. The score ranges from 0 for strong adherence to ASI to 8 for very weak adherence. At visit 2 : 3 to 12 weeks
Secondary Catheterization Adherence Scale (I-CAS) This is a patient questionnaire validated in French with 8 questions, 7 of which have a binary response (yes/no), and one with 5 suggested answers. The score ranges from 0 for strong adherence to ASI to 8 for very weak adherence. At visit 3 : 6 months
Secondary Intermittent Catheterization Acceptance Test (I-CAT) questionnaire The I-CAT allows for a better assessment and understanding of the psychological barriers encountered by patients in relation to ISA. The questionnaire consists of 14 questions, with a minimum score of 0 for perfect acceptance and a maximum score of 56 characterizing the least possible acceptance. At baseline
See also
  Status Clinical Trial Phase
Withdrawn NCT05538273 - Optimal Management of Urinary Catheter in Gyn Onc
Completed NCT04236596 - Pudendal Nerve Mapping Towards Improved Neuromodulation for Urinary Retention N/A
Completed NCT05526651 - Improvement of Urinary Retention Symptoms With Electroacupuncture Therapy N/A
Not yet recruiting NCT06070545 - The Effect of Modified Supine Position on Urinary Elimination After Percutaneous Coronary Intervention N/A
Recruiting NCT03314025 - Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery Phase 2
Recruiting NCT05439902 - Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women N/A
Enrolling by invitation NCT05259800 - Peppermint Oil for Urinary Retention N/A
Recruiting NCT06417346 - Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients N/A
Completed NCT03296280 - Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Completed NCT04715971 - Urinary Retention on an Acute Geriatric Hospitalisation Unit.
Completed NCT03302936 - Assessing Pyridium for Post-Sling Urinary Retention Phase 4
Completed NCT02886143 - Effect of Active vs. Passive Voiding Trials on Time to Discharge, Urinary Tract Infection, and Urinary Retention Phase 3
Completed NCT02749188 - Evaluation of Bladder Stimulation as a Noninvasive Technique of Urine Collection in Infant Who Have Not Acquired Walking N/A
Completed NCT01284361 - Comparison of Two Intermittent Urinary Catheters N/A
Completed NCT01220362 - Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study N/A
Terminated NCT00804557 - Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization N/A
Terminated NCT00563654 - Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up N/A
Terminated NCT00563485 - Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up N/A
Terminated NCT04682366 - The Effect of Tamsulosin on Postoperative Urinary Retention Phase 4
Terminated NCT03843073 - Connected Catheter- Safety and Effectiveness Study N/A